Toxicity evaluation
The occurrence of toxicity was retrospectively collected according to
history record and laboratory test record. Suspected related adverse
events including lethargy, arthralgia, edema, headache, vomiting,
nausea, stomachache, dizziness, constipation, diarrhea, distension of
the abdomen, peripheral neuropathy (numbness of extremities), chest
tightness, skin rash, were recorded. White blood cell counts, absolute
neutrophil count, platelet counts, aspartate aminotransferase levels,
alanine aminotransferase levels, total bilirubin levels, γ-glutamyl
transpeptidase, creatine levels, blood urea nitrogen levels were also
recorded. Adverse events and toxicity were graded by modified Common
Terminology Criteria for Adverse Events (CTCAE) v5.0. According to the
guidance from off-label medicine committee, reduced dose or withdrawal
thalidomide was performed if grade III/IV adverse events occurred.